title: A renaissance in the medical treatment of advanced prostate cancer.
abstract: Prostate cancer will be diagnosed in one of six men during their lifetimes, and a small portion of these will progress after primary and salvage therapies. For many years, there were few treatment options for these patients after routine hormonal maneuvers, and standard of care since the early 2000s has consisted primarily of docetaxel, which improved survival over the previous first-line therapy mitoxantrone. In recent years, however, new therapies have begun to emerge to treat this devastating form of prostate cancer. This review examines the mechanisms behind these therapeutics and the key trials seeking to validate their clinical use.
authors.affiliation: Division of Urology, University of Colorado Denver School of Medicine, Aurora, Colorado 80045, USA.
authors.forename: Kyle O
authors.initials: KO
authors.lastname: Rove
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Flaig
mesh_terms: D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D000069448:Denosumab; D006801:Humans; D007167:Immunotherapy; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D053245:RANK Ligand / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use; D014020:Tissue Extracts / Q000627:therapeutic use
chemical_list: D000736:Androstenes; D000737:Androstenols; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D053245:RANK Ligand; D043823:Taxoids; D014020:Tissue Extracts; D010669:Phenylthiohydantoin; D000069448:Denosumab; C552428:cabazitaxel; C511774:sipuleucel-T; C540278:enzalutamide; C089740:abiraterone